98 related articles for article (PubMed ID: 2679622)
21. Antisense phosphorodiamidate morpholino oligomer length and target position effects on gene-specific inhibition in Escherichia coli.
Deere J; Iversen P; Geller BL
Antimicrob Agents Chemother; 2005 Jan; 49(1):249-55. PubMed ID: 15616302
[TBL] [Abstract][Full Text] [Related]
22. Concentration and extinction coefficient determination for oligonucleotides and analogs using a general phosphate analysis.
Murphy JH; Trapane TL
Anal Biochem; 1996 Sep; 240(2):273-82. PubMed ID: 8811921
[TBL] [Abstract][Full Text] [Related]
23. Systemically delivered antisense oligomers upregulate gene expression in mouse tissues.
Sazani P; Gemignani F; Kang SH; Maier MA; Manoharan M; Persmark M; Bortner D; Kole R
Nat Biotechnol; 2002 Dec; 20(12):1228-33. PubMed ID: 12426578
[TBL] [Abstract][Full Text] [Related]
24. Phosphoramidate oligonucleotides as potent antisense molecules in cells and in vivo.
Faria M; Spiller DG; Dubertret C; Nelson JS; White MR; Scherman D; Hélène C; Giovannangeli C
Nat Biotechnol; 2001 Jan; 19(1):40-4. PubMed ID: 11135550
[TBL] [Abstract][Full Text] [Related]
25. Selective binding of trisamine-modified phosphorothioate antisense DNA to target mRNA improves antisense activity and reduces toxicity.
Matsukura M; Okamoto T; Miike T; Sawai H; Shinozuka K
Biochem Biophys Res Commun; 2002 May; 293(5):1341-7. PubMed ID: 12054660
[TBL] [Abstract][Full Text] [Related]
26. The synthesis and biological activities of oligodeoxynucleotides that are covalently linked to psoralen at their 5' ends.
Wang LX; Yang DC; Lu YY; Takagi Y; Taira K; Li T; Zhang LH
Drug Des Discov; 1995 Nov; 13(2):109-21. PubMed ID: 8872455
[TBL] [Abstract][Full Text] [Related]
27. Hairpin antisense oligonucleotides containing 2'-methoxynucleosides with base-pairing in the stem region at the 3'-end: penetration, localization, and Anti-HIV activity.
Kuwasaki T; Hosono K; Takai K; Ushijima K; Nakashima H; Saito T; Yamamoto N; Takaku H
Biochem Biophys Res Commun; 1996 Nov; 228(2):623-31. PubMed ID: 8920960
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of Ras p21 synthesis by antisense undecamers with uniform and specifically arranged phosphorothioate linkages.
Rait A; Uhlmann E; Peyman A; Will DW; Chang EH
Anticancer Drugs; 2000 Mar; 11(3):181-91. PubMed ID: 10831277
[TBL] [Abstract][Full Text] [Related]
29. Antisense inhibition of ras p21 expression that is sensitive to a point mutation.
Chang EH; Miller PS; Cushman C; Devadas K; Pirollo KF; Ts'o PO; Yu ZP
Biochemistry; 1991 Aug; 30(34):8283-6. PubMed ID: 1883816
[TBL] [Abstract][Full Text] [Related]
30. In vitro efficacy of morpholino-modified antisense oligomers directed against tumor necrosis factor-alpha mRNA.
Taylor MF; Paulauskis JD; Weller DD; Kobzik L
J Biol Chem; 1996 Jul; 271(29):17445-52. PubMed ID: 8663413
[TBL] [Abstract][Full Text] [Related]
31. Modified oligonucleotides in rabbit reticulocytes: uptake, stability and antisense properties.
Boiziau C; Toulmé JJ
Biochimie; 1991 Nov; 73(11):1403-8. PubMed ID: 1799634
[TBL] [Abstract][Full Text] [Related]
32. Comparative hybrid arrest by tandem antisense oligodeoxyribonucleotides or oligodeoxyribonucleoside methylphosphonates in a cell-free system.
Maher LJ; Dolnick BJ
Nucleic Acids Res; 1988 Apr; 16(8):3341-58. PubMed ID: 2836793
[TBL] [Abstract][Full Text] [Related]
33. Interactions of oligonucleotide analogs containing methylphosphonate internucleotide linkages and 2'-O-methylribonucleosides.
Kean JM; Cushman CD; Kang H; Leonard TE; Miller PS
Nucleic Acids Res; 1994 Oct; 22(21):4497-503. PubMed ID: 7526343
[TBL] [Abstract][Full Text] [Related]
34. Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice.
DeLong RK; Nolting A; Fisher M; Chen Q; Wickstrom E; Kligshteyn M; Demirdji S; Caruthers M; Juliano RL
Antisense Nucleic Acid Drug Dev; 1997 Apr; 7(2):71-7. PubMed ID: 9149842
[TBL] [Abstract][Full Text] [Related]
35. Phosphoroselenoate oligodeoxynucleotides: synthesis, physico-chemical characterization, anti-sense inhibitory properties and anti-HIV activity.
Mori K; Boiziau C; Cazenave C; Matsukura M; Subasinghe C; Cohen JS; Broder S; Toulmé JJ; Stein CA
Nucleic Acids Res; 1989 Oct; 17(20):8207-19. PubMed ID: 2682524
[TBL] [Abstract][Full Text] [Related]
36. alpha-DNA. VI: Comparative study of alpha- and beta-anomeric oligodeoxyribonucleotides in hybridization to mRNA and in cell free translation inhibition.
Gagnor C; Bertrand JR; Thenet S; Lemaître M; Morvan F; Rayner B; Malvy C; Lebleu B; Imbach JL; Paoletti C
Nucleic Acids Res; 1987 Dec; 15(24):10419-36. PubMed ID: 2447562
[TBL] [Abstract][Full Text] [Related]
37. Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages.
Shoji Y; Akhtar S; Periasamy A; Herman B; Juliano RL
Nucleic Acids Res; 1991 Oct; 19(20):5543-50. PubMed ID: 1658734
[TBL] [Abstract][Full Text] [Related]
38. A competitive enzyme hybridization assay for plasma determination of phosphodiester and phosphorothioate antisense oligonucleotides.
Deverre JR; Boutet V; Boquet D; Ezan E; Grassi J; Grognet JM
Nucleic Acids Res; 1997 Sep; 25(18):3584-9. PubMed ID: 9278477
[TBL] [Abstract][Full Text] [Related]
39. Antisense oligodeoxynucleotides as specific tools for studying neuroendocrine and behavioral functions: some prospects and problems.
Nicot A; Pfaff DW
J Neurosci Methods; 1997 Jan; 71(1):45-53. PubMed ID: 9125374
[TBL] [Abstract][Full Text] [Related]
40. An approach for new anticancer drugs: oncogene-targeted antisense DNA.
Schwab G; Duroux I; Chavany C; Hélène C; Saison-Behmoaras E
Ann Oncol; 1994; 5 Suppl 4():55-8. PubMed ID: 8060898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
